Observes glofitamab use in Chinese adults with relapsed lymphoma
Studies how glofitamab works in routine care for adults with returned diffuse large B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06656234
- Record updated
- 24 October 2024
- Original description
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.Read full original descriptionShow less
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
Inclusion: Be diagnosed as R/R DLBCL; Participants who will be treated with glofitamab (known as being recommended and having the intention to be treated with glofitamab at the time of signing informed consent) or have initiated glofitamab treatment within 6 months prior to enrollment and after the indication approval will be observed in this study.
Exclusion: Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.